CD33 splice site genotype was not associated with outcomes of patients receiving the anti-CD33 drug conjugate SGN-CD33A.

Abstract

We tested whether a single nucleotide polymorphism (SNP) that affects splicing of CD33 predicted response to treatment in adults with acute myeloid leukemia (AML) who received the novel CD33 antibody-drug conjugate SGN-CD33A. This genotype, for the CD33 splice site SNP rs12459419, was not associated with clinical response (30% CR/CRi in both groups), event-free survival, or overall survival.

• Authors: Michele Stanchina, Alessandro Pastore, Sean Devlin, Christopher Famulare, Eytan Stein, Justin Taylor
• Journal: Journal of hematology & oncology (J Hematol Oncol) Vol. 12 Issue 1 Pg. 85 (08 22 2019) ISSN: 1756-8722 [Electronic] England
• PMID: 31439003 (Publication Type: Letter, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)

Chemical References

• Antibodies, Monoclonal, Humanized
• Antineoplastic Agents, Immunological
• CD33 protein, human
• Immunoconjugates
• Sialic Acid Binding Ig-like Lectin 3
• lintuzumab

Topics

• Adult
• Aged
• Aged, 80 and over
• Antibodies, Monoclonal, Humanized (administration & dosage)
• Antineoplastic Agents, Immunological (administration & dosage)
• Female
• Genotype
• Humans
• Immunoconjugates (administration & dosage, immunology)
• Leukemia, Myeloid, Acute (drug therapy, genetics, immunology)
• Male
• Middle Aged
• Polymorphism, Single Nucleotide
• RNA Splicing
• Sialic Acid Binding Ig-like Lectin 3 (genetics, immunology)
• Survival Rate
• Treatment Outcome